You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Details for New Drug Application (NDA): 202714

✉ Email this page to a colleague

NDA 202714 describes KYPROLIS, which is a drug marketed by Onyx Pharms Amgen and is included in one NDA. It is available from one supplier. There are four patents protecting this drug and three Paragraph IV challenges. Additional details are available on the KYPROLIS profile page.

The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the carfilzomib profile page.

Summary for 202714

Tradename:	KYPROLIS
Applicant:	Onyx Pharms Amgen
Ingredient:	carfilzomib
Patents:	4

Pharmacology for NDA: 202714

Mechanism of Action	Proteasome Inhibitors

Suppliers and Packaging for NDA: 202714

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714	NDA	Onyx Pharmaceuticals, Inc.	76075-101	76075-101-01	1 VIAL, SINGLE-USE in 1 CARTON (76075-101-01) / 30 mL in 1 VIAL, SINGLE-USE
KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714	NDA	Onyx Pharmaceuticals, Inc.	76075-101	76075-101-21	1 VIAL, SINGLE-USE in 1 CARTON (76075-101-21) / 30 mL in 1 VIAL, SINGLE-USE

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	POWDER;INTRAVENOUS			Strength	60MG/VIAL
Approval Date:	Jul 20, 2012	TE:	AP	RLD:	Yes
Regulatory Exclusivity Expiration:	May 22, 2028
Regulatory Exclusivity Use:	ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
Regulatory Exclusivity Expiration:	Nov 22, 2028
Regulatory Exclusivity Use:	PEDIATRIC EXCLUSIVITY
Patent:	7,417,042*PED	Patent Expiration:	Jan 20, 2027	Product Flag?		Substance Flag?		Delist Request?	Y

Expired US Patents for NDA 202714

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Onyx Pharms Amgen	KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714-001	Jul 20, 2012	7,232,818	⤷ Start Trial
Onyx Pharms Amgen	KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714-002	Jun 3, 2016	8,207,127	⤷ Start Trial
Onyx Pharms Amgen	KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714-003	Jun 7, 2018	7,232,818	⤷ Start Trial
Onyx Pharms Amgen	KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714-002	Jun 3, 2016	7,232,818	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.